US 12,298,310 B2
Methods for cancer detection with quantum dots
Wei-Heng Shih, Bryn Mawr, PA (US); Wan Y. Shih, Bryn Mawr, PA (US); Giang Au, Sicklerville, NJ (US); Ari D. Brooks, Cherry Hill, NJ (US); and Vanlila K. Swami, Philadelphia, PA (US)
Assigned to Drexel University, Philadelphia, PA (US)
Filed by Wei-Heng Shih, Bryn Mawr, PA (US); Wan Y. Shih, Bryn Mawr, PA (US); Giang Au, Sicklerville, NJ (US); Ari D. Brooks, Cherry Hill, NJ (US); and Vanlila K. Swami, Philadelphia, PA (US)
Filed on Dec. 2, 2019, as Appl. No. 16/700,677.
Application 16/700,677 is a division of application No. 15/202,710, filed on Jul. 6, 2016, granted, now 10,527,625.
Application 15/202,710 is a continuation of application No. 14/119,996, granted, now 9,417,240, issued on Aug. 16, 2016, previously published as PCT/US2012/039532, filed on May 25, 2012.
Prior Publication US 2020/0141940 A1, May 7, 2020
Int. Cl. G01N 33/574 (2006.01); B82Y 15/00 (2011.01); C07K 16/22 (2006.01); C07K 16/30 (2006.01); G01N 33/532 (2006.01); G01N 33/533 (2006.01); G01N 33/551 (2006.01); G01N 33/58 (2006.01); B82Y 5/00 (2011.01); B82Y 40/00 (2011.01)
CPC G01N 33/57488 (2013.01) [B82Y 15/00 (2013.01); C07K 16/22 (2013.01); C07K 16/30 (2013.01); G01N 33/532 (2013.01); G01N 33/533 (2013.01); G01N 33/551 (2013.01); G01N 33/574 (2013.01); G01N 33/57484 (2013.01); G01N 33/57492 (2013.01); G01N 33/588 (2013.01); B82Y 5/00 (2013.01); B82Y 40/00 (2013.01); G01N 2333/475 (2013.01); G01N 2333/705 (2013.01); G01N 2400/00 (2013.01); G01N 2458/00 (2013.01); Y10S 977/774 (2013.01); Y10S 977/824 (2013.01); Y10S 977/892 (2013.01); Y10S 977/927 (2013.01)] 18 Claims
 
1. A method for cancer detection, wherein the method comprises the steps of:
a) contacting conjugated quantum dots to tissue, wherein each of said conjugated quantum dots comprises a quantum dot conjugated to a biomarker specific moiety selected from the group consisting of anti-VEGF antibodies, anti-Tn antigen antibodies, anti-T antigen antibodies, anti-sial-T antigen antibodies, anti-sial-Tn antigen antibodies, anti-HER2 antibodies and anti-IGFR antibodies, for a time sufficient to bind at least some of said conjugated quantum dots to a biomarker on the tissue;
b) removing unbound conjugated quantum dots from the tissue,
c) exciting said bound conjugated quantum dots with excitation energy, and
d) analyzing an emission from the bound conjugated quantum dots to detect a presence of cancer,
wherein the quantum dots have a core selected from the group consisting of CdSe, CdTe, CdPbS, and ZnSnS and said quantum dots are capped with a mercaptocarboxylic acid capping agent and at least part of said mercaptocarboxylic acid capping agent is replaced with mercaptosilane capping agent and the molar ratio the capping agents:metal:Se, Te or S is from about 2:1:1 to about 16:8:1.